NEWS FROM SWEDENBIO
In Japan, opportunities abound for Swedish life science07 Nov 2023
Three life science-professionals share their experience and insights from the Japanese life science-sector and the many untapped opportunities for Swedish companies.
Input to the research plug defends the fundamentals of research31 Oct 2023
Increase funding, remove micromanagement and increase visibility – these are SwedenBIO’s main recommendations in the input to the recently submitted research bill.
The Nordic region’s largest life science event turns ten years old18 Oct 2023
Nordic Life Science Days is celebrating its anniversary and is being held for the first time in Copenhagen.
Nordic Life Science Days
SwedenBIO annually organizes the largest partnering conference in the Nordic region – Nordic Life Science Days. Present your company to an international audience at home, participate in partnering meetings and take part in a packed stage program!
Swedish Pipeline Report
The Swedish Drug Discovery and Development Pipeline Report 2023 contains a mapping of drug development projects by companies headquartered in Sweden. Read it for a solid insight into the Swedish life science industry.
Business & Finance
How to create sustainable trading on the stock exchange
The life science sector is one of the strongest for listed small companies in Sweden. At the same time, the competition in the sector is fierce and it is necessary to work with the issues that affect share trading. A well-functioning share trading is important for creating growth in small and medium-sized companies.
Offer to you as an incubator company
Life for startup companies was not without challenges before the effects of the corona crisis hit, and the situation is now tough for many smaller companies. Now we want to contribute to building Sweden’s next generation of life science companies strong, for future export revenue and innovation power. Startup companies with up to four employees must be members of SwedenBIO for an annual fee of SEK 1,000.
What does the future look like for dual listings in the US? When is the right time? These are questions Adam Kostyal devotes himself to answering in the latest episode of Brännpunkt Life Science.
Brännpunkt Life Science is an interview series in collaboration with DNB Sweden that focuses the magnifying glass on the intersection between innovation, capital and health. In the first part, we meet Adam Kostyal, European head of listing at Nasdaq, who looks at how the stock market year looked for the sector, talks about the impact of the pandemic and shares his predictions for the future.
Fast facts from “The Swedish Drug Discovery and Development Pipeline 2023”
Companies headquartered in Sweden are currently researching new medicines.
Pharmaceutical projects underway, more than 100 in the field of cancer
Of the pharmaceutical companies are from academia or health care sector